Carlo Colosimo, MD, FEAN, Santa Maria University Hospital, Terni, Italy, discusses current advances in the development of novel therapies for multiple system atrophy (MSA). Recently, various trials evaluated neuroprotective strategies in MSA patients, and although the results were negative, they provided great proof of concept for future large multinational clinical trials. Additionally, improved animal models have been helpful for preclinically testing potential compounds, thus paving the way for the development of treatments to delay the progressive neurodegeneration of MSA. While disease-modifying therapies aren’t available, symptomatic treatment remains essential to maintain the patient’s quality of life. This interview took place at the 2022 International Congress of Parkinson’s disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
